Boston, MA, United States of America

Thomas Einhorn

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Warsaw Orthopedic, Inc.. Active years: 2013.


% Patents Active = 100.0


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Einhorn - Innovator in Joint Revision Implants

Introduction

Thomas Einhorn is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of orthopedic implants, particularly in joint revision procedures. His innovative approach focuses on enhancing bone healing and integration for cementless implants.

Latest Patents

Einhorn holds a patent for a joint revision implant. This osteoconductive backing implant is designed to improve bone healing and facilitate bony integration of the implant. The implant features a generally planar surface that can be shaped into a hemispherical form. One embodiment of the implant includes a disc with an inner hole and an outer edge, featuring at least one slit extending from the inner hole to the outer edge. The disc is constructed from a coherent mass of elongate, mechanically entangled demineralized bone particles. He has 1 patent to his name.

Career Highlights

Einhorn is associated with Warsaw Orthopedic, Inc., where he applies his expertise in developing advanced orthopedic solutions. His work has been instrumental in improving patient outcomes in joint revision surgeries.

Collaborations

Einhorn has collaborated with notable colleagues, including Kenneth C Petersen and David L Reed, contributing to the advancement of orthopedic technologies.

Conclusion

Thomas Einhorn's innovative work in joint revision implants showcases his commitment to enhancing orthopedic care. His contributions are paving the way for improved surgical outcomes and patient recovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…